Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.49 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CTSA | P10619 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | CES1 | P23141 | 1/20 | 0.46 |
| ▸ | GNA15 | P30679 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31326036 | 0.89 | KMT2A (0.70) | KMT2AL3MBTL1MTNR1AMTNR1BCES2 | |
| SCHEMBL10769339 | 0.87 | FFAR1 (0.54) | KMT2AFFAR1 | |
| SCHEMBL10600717 | 0.86 | FFAR1 (0.58) | KMT2AFFAR1GNA15 | |
| SCHEMBL5181398 | 0.85 | KMT2A (0.49) | KMT2AFFAR1L3MBTL1MTNR1AMTNR1B | |
| SCHEMBL1369506 | 0.85 | KMT2A (0.55) | KMT2AFFAR1L3MBTL1MTNR1AMTNR1B | |
| SCHEMBL13100658 | 0.85 | KMT2A (0.79) | KMT2AFFAR1L3MBTL1LMNACES2 | |
| SCHEMBL21656331 | 0.84 | KMT2A (0.54) | KMT2AFFAR1L3MBTL1MTNR1AMTNR1B | |
| SCHEMBL9230531 | 0.83 | KMT2A (0.51) | KMT2AL3MBTL1MTNR1AMTNR1BCES2 | |
| SCHEMBL9393589 | 0.83 | L3MBTL1 (0.60) | KMT2AFFAR1L3MBTL1MTNR1AMTNR1B | |
| SCHEMBL11155395 | 0.82 | L3MBTL1 (0.48) | KMT2AFFAR1L3MBTL1MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11136296-B2 | Substituted N-arylethyl-2-arylquinoline-4-carboxamides and use thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2021-10-05 | — | — | US | disclosed |
| US-20200031775-A1 | SUBSTITUTED N-ARYLETHYL-2-ARYLQUINOLINE-4-CARBOXAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200031775-A1 | SUBSTITUTED N-ARYLETHYL-2-ARYLQUINOLINE-4-CARBOXAMIDES AND USE THEREOF | AADAC, NAT1, EPX | KMT2A 921/4885FFAR1 781/4885L3MBTL1 3686/4885 |
| US-11136296-B2 | Substituted N-arylethyl-2-arylquinoline-4-carboxamides and use thereof | AADAC, NAT1, EPX | KMT2A 921/4885FFAR1 781/4885L3MBTL1 3686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.